Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.87 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.87 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.87 |
| ▸ | HMGCR | P04035 | 5/20 | 0.82 |
| ▸ | RXRA | P19793 | 3/20 | 0.82 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14569976 | 1.00 | NR4A2 (0.87) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| SCHEMBL14569977 | 1.00 | NR4A2 (0.87) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL6068297 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278902 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL6068293 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL10049191 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL3369 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL1582325 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2870889 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278898 | 0.93 | PDE4D (1.00) | NR4A2PDE4DNR1I2HMGCRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9517233-B2 | Local cochlear application of statins for stimulating neurite regrowth in the cochlea | NORTHWESTERN UNIVERSITY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160022663-A1 | LOCAL COCHLEAR APPLICATION OF STATINS FOR STIMULATING NEURITE REGROWTH IN THE COCHLEA | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2016-01-28 | — | — | US | disclosed |
| US-20160015819-A1 | FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS: COMPOSITIONS AND METHODS OF USE | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9084826-B2 | Fatty acid conjugates of statin and FXR agonists; compositions and method of uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140127295-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | Cellworks Group, Inc (US) | 2014-05-08 | — | — | US | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-20130072688-A1 | METHOD FOR PREPARING AN INTERMEDIATE OF PITAVASTATIN OR OF THE SALT THEREOF | H.L. GENOMICS (KR) | 2013-03-21 | — | — | US | disclosed |
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-01-19 | — | — | US | disclosed |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2009-11-05 | — | — | US | disclosed |
| US-20080312462-A1 | Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives | SEDELMEIER GOTTFRIED | 2008-12-18 | — | — | US | disclosed |
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | ACEMOGLU MURAT | 2008-07-31 | — | — | US | disclosed |
| US-7371865-B2 | Process for the manufacture of HMG-CoA reductase inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2008-05-13 | — | — | US | disclosed |
| US-7335757-B2 | Carbonyl reductase, gene encoding the same, and process for producing optically active alcohols using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2008-02-26 | — | — | US | disclosed |
| US-20070155970-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORY MEVALONIC ACID DERIVATIVES | SEDELMEIER GOTTFRIED | 2007-07-05 | — | — | US | disclosed |
| US-7208623-B2 | Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives | NOVARTIS AG (CH) | 2007-04-24 | — | — | US | disclosed |
| US-7193086-B2 | Process for preparation of a quinolinecarbaldehyde | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312462-A1 | Process for the manufacture of HMG-CoA reductase inhibitory mevalonic acid derivatives | HMGCR, COASY, DHCR7 | NR4A2 4293/4885PDE4D 3066/4885NR1I2 626/4885 |
| US-20080182873-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORS | HMGCR, COASY, DHCR7 | NR4A2 3561/4885PDE4D 3207/4885NR1I2 493/4885 |
| US-20120016129-A1 | Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof | PCSK9, HMGCR, HDLBP | NR4A2 3911/4885PDE4D 579/4885NR1I2 3388/4885 |
| US-20070155970-A1 | PROCESS FOR THE MANUFACTURE OF HMG-COA REDUCTASE INHIBITORY MEVALONIC ACID DERIVATIVES | HMGCR, COASY, DHCR7 | NR4A2 4188/4885PDE4D 2938/4885NR1I2 997/4885 |
| US-20130072688-A1 | METHOD FOR PREPARING AN INTERMEDIATE OF PITAVASTATIN OR OF THE SALT THEREOF | DPP4, REN, DPP7 | NR4A2 3647/4885PDE4D 200/4885NR1I2 4730/4885 |
| US-20140127295-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | TNF, C5, C9 | NR4A2 3354/4885PDE4D 646/4885NR1I2 3664/4885 |
| US-20160022663-A1 | LOCAL COCHLEAR APPLICATION OF STATINS FOR STIMULATING NEURITE REGROWTH IN THE COCHLEA | NGF, BDNF, NLN | NR4A2 2373/4885PDE4D 214/4885NR1I2 3837/4885 |
| US-20160015819-A1 | FATTY ACID CONJUGATES OF STATIN AND FXR AGONISTS: COMPOSITIONS AND METHODS OF USE | SLC10A1, NR1H4, FXR1 | NR4A2 831/4885PDE4D 2176/4885NR1I2 160/4885 |
| US-20090275752-A1 | Novel Process for Statins and its Pharmaceutically Acceptable Salts Thereof | HMGCR, NPC1L1, PCSK9 | NR4A2 4110/4885PDE4D 1145/4885NR1I2 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.